VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Receives Consensus Recommendation of “Reduce” from Analysts

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) has received a consensus rating of “Reduce” from the five research firms that are currently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating and four have issued a hold rating on the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $0.95.

A number of analysts recently commented on the stock. Wall Street Zen cut shares of VistaGen Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 21st. Weiss Ratings restated a “sell (e+)” rating on shares of VistaGen Therapeutics in a research note on Wednesday, June 3rd.

Hedge Funds Weigh In On VistaGen Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Cubist Systematic Strategies LLC acquired a new position in shares of VistaGen Therapeutics in the 1st quarter valued at about $25,000. Schonfeld Strategic Advisors LLC acquired a new stake in VistaGen Therapeutics during the third quarter worth about $39,000. Boothbay Fund Management LLC boosted its position in VistaGen Therapeutics by 10.8% in the 3rd quarter. Boothbay Fund Management LLC now owns 197,024 shares of the company’s stock worth $699,000 after purchasing an additional 19,166 shares in the last quarter. Bank of America Corp DE grew its stake in shares of VistaGen Therapeutics by 1,068.0% during the 4th quarter. Bank of America Corp DE now owns 21,141 shares of the company’s stock worth $62,000 after purchasing an additional 19,331 shares during the period. Finally, Millennium Management LLC purchased a new position in shares of VistaGen Therapeutics during the 3rd quarter valued at approximately $73,000. Hedge funds and other institutional investors own 78.39% of the company’s stock.

VistaGen Therapeutics Price Performance

Shares of VTGN remained flat at $0.25 during midday trading on Friday. The stock had a trading volume of 4,377,172 shares, compared to its average volume of 4,163,570. VistaGen Therapeutics has a 12-month low of $0.20 and a 12-month high of $5.14. The company’s 50-day moving average is $0.59 and its two-hundred day moving average is $0.66. The firm has a market cap of $10.21 million, a PE ratio of -0.14 and a beta of 0.40.

VistaGen Therapeutics (NASDAQ:VTGN) last announced its earnings results on Monday, June 15th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.03). VistaGen Therapeutics had a negative return on equity of 133.02% and a negative net margin of 5,487.01%.The business had revenue of $0.38 million for the quarter, compared to analysts’ expectations of $0.40 million. During the same quarter last year, the firm earned ($1.67) earnings per share. As a group, research analysts expect that VistaGen Therapeutics will post -1.32 EPS for the current fiscal year.

About VistaGen Therapeutics

VistaGen Therapeutics, Inc (NASDAQ:VTGN) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation medicines for central nervous system disorders. Incorporated in Delaware in 1998 and headquartered in South San Francisco, California, VistaGen applies advanced human pluripotent stem cell technologies to accelerate drug candidate validation and optimization. The company’s core focus is on addressing unmet medical needs in major depressive disorder, neuropathic pain and dermatological conditions.

The company’s lead candidate, AV-101, is an oral prodrug designed to modulate glutamatergic neurotransmission via the N-methyl-D-aspartate (NMDA) receptor pathway, with clinical programs targeting major depressive disorder and neuropathic pain.